Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
复制标题
DOI：
10.1200/jco.2004.09.070
复制
发表时间：
2004-05-01
影响因子：
45.3
通讯作者：
Olivotto, IA
中科院分区：
文献类型：
--
作者：
Chia, SK;Speers, CH;Olivotto, IA
目的：为了讨论辅助系统治疗的绝对益处，需要了解长期结局和基线复发风险以及疾病特异性生存率。我们评估了10年的结果，在一个以人群为基础的队列淋巴结阴性（N-）淋巴血管阴性（LV-）早期乳腺癌诊断从1989年至1991年谁没有接受辅助全身therapy.Methods 1187例pT（1-2）N（0），LV-乳腺癌的中位数随访10.4年进行了审查。Kaplan-Meier生存曲线的无复发生存期（RFS），乳腺癌特异性生存期（BCSS）和总生存期（OS）进行了比较与对数秩检验与队列分层的肿瘤大小和gradient.Results这个系列的中位年龄为62岁。430个肿瘤直径为：1 cm（队列1），507个为1.1-2 cm（队列2），250个为2.1 - 5 cm（队列3）。队列1、队列2和队列3的10年结局分别存在显著差异：RFS分别为82%、75%和66%; BCSS分别为92%、90%和77%; OS分别为79%、78%和66%。肿瘤分级显着改变的结果内的大小cohort，特别是在pT（1）N（0）breast cancer.Conclusion这项研究提供了详细的信息，继续复发和乳腺癌死亡率，以10年的后续行动。具体而言，在没有辅助全身治疗的情况下，如果LV-、N -乳腺癌患者具有3级肿瘤：1 cm、2 - 3级肿瘤1.1 - 2 cm或任何大于2 cm的等级肿瘤，则其10年复发风险大于或等于25%，相应的10年乳腺癌死亡率大于或等于10%。
Purpose To discuss the absolute benefits from adjuvant systemic therapy knowledge of long-term outcomes and baseline risks of relapse and disease-specific survival are required. We assessed the 10-year outcomes in a population-based cohort of node-negative (N-) lymphovascular negative (LV-) early breast cancers diagnosed from 1989 to 1991 who did not receive adjuvant systemic therapy.Methods One thousand one hundred eighty-seven cases of pT(1-2)N(0), LV- breast cancers with a median follow-up of 10.4 years were reviewed. Kaplan-Meier survival curves for relapse free survival (RFS), breast cancer-specific survival (BCSS) and overall survival (OS) were compared with log-rank tests with cohorts stratified for tumor size and grade.Results The median age of this series was 62 years. Four hundred thirty tumors were : 1 cm in diameter (cohort 1), 507 were 1.1-2 cm (cohort 2), and 250 were 2.1 to 5 cm in diameter (cohort 3). The 10-year outcomes for cohorts 1, 2, and 3, respectively, were significantly different: RFS, 82%, 75%, and 66%; BCSS, 92%, 90%, and 77%; and OS, 79%, 78%, and 66%. Tumor grade significantly altered outcome within size cohorts, particularly in pT(1)N(0) breast cancers.Conclusion This study provides detailed information on the continued relapse and breast cancer death rate to 10 years of follow-up. Specifically, without adjuvant systemic therapy, patients with LV-, N - breast cancer had a greater than or equal to 25% 10-year risk of relapse and a corresponding 10-year breast cancer death rate of greater than or equal to 10% if they had either a grade 3 tumor : 1 cm, a grade 2 to 3 tumor from 1.1 to 2 cm, or any grade tumor greater than 2 cm.